Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The Invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the Invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and sorbitol. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior and stability.

Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.

Abstract: Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and sorbitol. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystal-lization behaviour and stability.

Abstract: The invention is directed to a process for the preparation of ?,?-unsaturated acids, esters and amides from ?- or ?-hydroxycarboxylic acids or esters or precursors in high yields and high selectivity. The ?,?-unsaturated acids or esters are optionally prepared in the presence of specific dehydration and/or esterification catalysts. The ?,?-unsaturated amides or substituted amides are prepared optionally in the presence of a dehydration and/or amidation catalyst. The source of ?- or ?-hydroxycarboxylic acids or precusor is preferably from a renewable resource. The precursor is defined herein.

Abstract: The invention is directed to a process for the preparation of ?,?-unsaturated acids, esters and amides from ?- or ?-hydroxycarboxylic acids or esters or precursors in high yields and high selectivity. The ?,?-unsaturated acids or esters are optionally prepared in the presence of specific dehydration and/or esterification catalysts. The ?,?-unsaturated amides or substituted amides are prepared optionally in the presence of a dehydration and/or amidation catalyst. The source of ?- or ?-hydroxycarboxylic acids or precusor is preferably from a renewable resource. The precursor is defined herein.

Abstract: The invention is directed to a process for the preparation of ?,?-unsaturated acids, esters and amides from ?- or ?-hydroxycarboxylic acids or esters or precursors in high yields and high selectivity. The ?,?-unsaturated acids or esters are optionally prepared in the presence of specific dehydration and/or esterification catalysts. The ?,?-unsaturated amides or substituted amides are prepared optionally in the presence of a dehydration and/or amidation catalyst. The source of ?- or ?-hydroxycarboxylic acids or precusor is preferably from a renewable resource. The precursor is defined herein.

Abstract: Raney copper, which is doped (promoted) with an effective quantity of a doping (promoting) agent selected from the group boric acid, onium fluorides, salts of fluorine complex anions, and heteropoly acids, represents an outstanding oxidation catalyst for amine-group-containing primary amines to carboxylic acids.

Abstract: Raney copper, which is doped (promoted) with an effective quantity of a doping (promoting) agent selected from the group boric acid, onium fluorides, salts of fluorine complex anions, and heteropoly acids, represents an outstanding oxidation catalyst for amine-group-containing primary amines to carboxylic acids.

Abstract: Process for the preparation of amine-group-containing carboxylic acid salts by oxidation of amine-group-containing primary alcohols in an aqueous-alkaline reaction medium, in the presence of a copper catalyst, and at an elevated temperature, which is characterized in that the copper catalyst used is a reduced copper/chrome or copper/zinc spinel.

Abstract: Process for the preparation of N-phosphonomethylglycine salts by reacting a salt of N-phosphonomethyliminodiacetic acid, whereby the salt-forming cation is selected from the group alkali metals, alkaline earth metals, ammonium and organic ammonium, in the presence of oxygen in an aqueous-basic or aqueous solution and in the presence of a noble metal catalyst on a solid carrier, under excess pressure and at elevated temperature, the process being characterised by the fact that (a) the noble metal is selected from the group platinum, palladium or mixtures of palladium and platinum, and platinum or palladium individually or together in a mixture with ruthenium, rhodium, osmium or iridium, and (b) it is additionally admixed with at least one doping metal from the group bismuth, lead, tin, tellurium, germanium, vanadium, chromium, iron, manganese, molybdenum and tungsten. The known herbicide N-phosphonomethylglycine may be prepared from N-phosphono-methyliminodiacetic acid.